Bristol Myers Fundamental Trends Analysis

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

The Drivers Module shows relationships between Bristol Myers's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Bristol Myers Squibb over time as well as its relative position and ranking within its peers. Continue to Trending Equities

Search Current Fundamental Trends

 
Refresh
Bristol Myers Price to Sales Ratio is fairly stable at the moment as compared to the past year. Bristol Myers reported Price to Sales Ratio of 4.00 in 2019. Return on Sales is likely to grow to 0.20 in 2020, whereas Sales per Share is likely to drop 15.17 in 2020. Bristol Myers Consolidated Income is fairly stable at the moment as compared to the past year. Bristol Myers reported Consolidated Income of 3.46 Billion in 2019. Net Income to Non Controlling Interests is likely to grow to about 21.6 M in 2020, whereas Accumulated Other Comprehensive Income is likely to drop (1.6 B) in 2020.

Bristol Myers Squibb Cash Flow from Operations vs. Cash and Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth.
Bristol Myers Squibb is rated third in cash and equivalents category among related companies. It is rated fifth in cash flow from operations category among related companies making about  0.58  of Cash Flow from Operations per Cash and Equivalents. The ratio of Cash and Equivalents to Cash Flow from Operations for Bristol Myers Squibb is roughly  1.73 . Bristol Myers Cash and Equivalents is fairly stable at the moment as compared to the past year. Bristol Myers reported Cash and Equivalents of 12.35 Billion in 2019
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Bristol Myers 
Cash 
 = 
Bank Deposits 
+  
Liquidities 
=
18.32 B
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Bristol Myers 
Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
=
10.57 B
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Bristol Cash Flow from Operations Comparison

  Cash Flow from Operations 
      Bristol Myers Comparables 
Bristol Myers is rated fourth in cash flow from operations category among related companies.

Bristol Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page